Related Experiment Videos
Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells
E C Lattime1, L G Gomella, P A McCue
1Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
Cancer Research
|August 1, 1992
Summary
Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer works because tumors can present BCG antigens to T-cells. Interferon treatment enables tumor cells to express necessary molecules for this interaction, enhancing immune response.
Area of Science:
- Immunology
- Oncology
- Urology
Background:
- Intravesical Bacillus Calmette-Guérin (BCG) is a leading immunotherapy for superficial bladder cancer.
- The precise mechanism of BCG's efficacy, particularly its interaction with tumor cells, remains unclear.
Purpose of the Study:
- To investigate if bladder tumor cells can present antigens.
- To determine if bladder tumors can directly interact with BCG-specific T-cells.
Main Methods:
- Studied the murine bladder tumor cell line MB49, initially negative for MHC Class II (IA).
- Induced IA expression on MB49 cells using interferon (IFN).
- Assessed BCG antigen presentation to CD4+ T-cells from BCG-treated mice.
Main Results:
- Interferon-induced MB49 cells expressed MHC Class II (IA) both in vitro and in vivo.
- MB49 cells presented BCG antigens to specific CD4+ T-cells.
- This interaction led to the production of interleukin-2 and tumor necrosis factor in an antigen- and IA-dependent manner.
Conclusions:
- Epithelial tumor cells, like MB49, are capable of antigen presentation.
- This finding supports a direct interaction model between tumor cells and BCG-specific T-cells.
- Demonstrates a novel mechanism for BCG immunotherapy, opening avenues for enhanced cancer treatment strategies.